Artisan Partners Limited Partnership Raises Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Artisan Partners Limited Partnership boosted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 26.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,334,702 shares of the biopharmaceutical company's stock after purchasing an additional 278,610 shares during the period. Artisan Partners Limited Partnership owned about 0.85% of Ocular Therapeutix worth $11,398,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Ocular Therapeutix by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock valued at $72,453,000 after buying an additional 99,730 shares in the last quarter. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 0.6% in the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock worth $22,344,000 after acquiring an additional 16,300 shares in the last quarter. Braidwell LP grew its holdings in shares of Ocular Therapeutix by 36.3% during the third quarter. Braidwell LP now owns 2,239,770 shares of the biopharmaceutical company's stock worth $19,486,000 after purchasing an additional 596,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock worth $9,663,000 after acquiring an additional 21,025 shares during the last quarter. Finally, Rosalind Advisors Inc. increased its holdings in shares of Ocular Therapeutix by 27.5% in the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after purchasing an additional 243,700 shares in the last quarter. 59.21% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Donald Notman sold 11,119 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares in the company, valued at approximately $1,510,797.64. This trade represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,895 shares of company stock worth $283,772 in the last ninety days. Company insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

OCUL has been the topic of a number of analyst reports. Needham & Company LLC began coverage on Ocular Therapeutix in a research note on Tuesday, March 11th. They issued a "buy" rating and a $15.00 price target on the stock. JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $16.38.

Ocular Therapeutix Trading Up 7.6 %

NASDAQ OCUL traded up $0.50 during mid-day trading on Wednesday, reaching $7.04. 634,225 shares of the stock were exchanged, compared to its average volume of 1,542,034. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a market cap of $1.12 billion, a P/E ratio of -5.33 and a beta of 1.49. The stock has a 50 day simple moving average of $7.48 and a 200-day simple moving average of $8.73. Ocular Therapeutix, Inc. has a one year low of $4.06 and a one year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.